Alector News and Activities

Alector is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Alector is a company listed under the stock ticker ALEC (US).

View the org chart displaying its 23 main executives

Most searched biographies at Alector

• Arnon Rosenthal, Co-Founder, Chief Executive Officer and Director
• David Wehner, Director
• Richard Scheller, Director

Popular executive movements at Alector

• Giacomo Salvadore, who was Senior Vice President of Clinical Development, is promoted to Chief Medical Officer  (posted on April 2 2025).
• Gary Romano who was Chief Medical Officer, becomes Advisor  (posted on April 1 2025).

Create your alert
to follow the executive moves at Alector.

Alector has 2,341 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Biogen (United States (USA)).

Popular M&A news in Biotechnology

• Regeneron Pharmaceuticals has announced the acquisition of 23andMe  (posted on May 20 2025).
• Stylus Medicine has just announced a $85 Million fundraising (posted on May 16 2025).
• Azafaros has just announced a $132 Million fundraising (posted on May 15 2025).

Popular contacts in Biotechnology

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships at WIRB-Copernicus Group
• Deepika Verma - Associate Director of Data Science and Digitalization at Wheeler Bio
• Steven Gillis - Chairman of the Board at VBI Vaccines

Learn more about the Biotechnology industry

Press releases by Alector

• Alector to Participate at Virtual Investor Conferences in September | Alector
• Alector Reports Second Quarter 2020 Financial Results and Provides Corporate Update | Alector
• Alector to Present at the BTIG Virtual Biotechnology Conference 2020 | Alector
• Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal Dementia | Alector
• Alector Doses First Patient in Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 in Patients with Frontotemporal Dementia | Alector
• Alector to Present Data from the AL001 Phase 2 Open-Label Study in Frontotemporal Dementia at the 2020 Alzheimer’s Association International Conference | Alector
• Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002, a TREM2 Activating Antibody for the Treatment of Alzheimer’s Disease, in The Journal of Experimental Medicine | Alector
• Alector to Present at the Goldman Sachs 41st Annual Global Healthcare Conference | Alector
• Alector Reports 2020 First Quarter Financial Results and Business Highlights | Alector
• Alector to Present at the Bank of America Securities Virtual Health Care Conference | Alector
• View more press releases Close

Social media about Alector

• Alector on Wikipedia, Google News & Yahoo Finance
• Alector on LinkedIn, Twitter & YouTube